

iRhythm Holdings, Inc. (IRTC)


Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001388658

iRhythm Holdings, Inc. IRTC; healthcare	
Grade	A A B C D E strongest fifth of 371 graded peers percentile 7.3; sampling error 2.5 points; lower is stronger
Rank	28 of 371
Profitability	B percentile 26.7
Solvency	B/C percentile 38.9
Growth and financing	B percentile 27.0
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$1.0B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Feb 19, 2026 232 days before the rescans; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$102.84 2026-10-08; market equity \$3.4B
Price used in grade	None



A, the bull
 strongest fifth of its sector;
 letters are fifths of the 371
 graded peers


Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A/B from Feb 21, 2021, B from Mar 21, 2022, C from Mar 21, 2023

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

iRhythm is a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Our principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 26.7						
Gross profitability		51.7%	32.2%	21.3	372	2025-12-31
Return on invested capital		not computable	9.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		(12.9%)	(6.6%)	34.4	811	2025-12-31
Gross margin stability, five years		1.5 pts	2.8 pts	24.4	243	2025-12-31
Solvency, sleeve percentile 38.9						
Twelve-month failure probability		0.06%	0.07%	42.5	248	2026-06-30
Altman Z double-prime		0.78	(0.31)	34.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			required facts have no common fiscal period end latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Interest coverage		not computable	(4.51x)			
Current ratio		4.63x	2.96x	40.1	839	2025-12-31
Growth and financing, sleeve percentile 27.0						
Revenue growth, three-year compound		22.1%	10.0%	29.2	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000 pretax income must exceed the validity floor and imply a 0%-100% tax rate
Reinvestment rate		not computable	37.1%			
Asset growth, three years		31.5%	2.1%	14.9	704	2025-12-31
Net share issuance, one year		2.9%	2.5%	37.0	634	2026-02-12


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 117,872,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
23	SBC Medical Group Holdings Inc. (SBC)	6.1	A	fortress
24	SBC Medical Group Holdings Inc. (SBCWW)	6.1	A	balance sheet fortress
25	United Therapeutics Corp. (UTHR)	6.5	A	balance sheet
26	AtriCure, Inc. (ATRC)	6.8	A	
27	Intuitive Surgical Inc. (ISRG)	7.0	A	
28	iRhythm Holdings, Inc. (IRTC) <	7.3	A	fortress balance sheet
29	Globus Medical Inc. (GMED)	7.6	A	
30	Hims & Hers Health, Inc. (HIMS)	7.8	A	
31	Gyre Therapeutics, Inc. (GYRE)	8.1	A	fortress balance sheet
32	Veracyte, Inc. (VCYT)	8.4	A	
33	Alkermes plc. (ALKS)	8.6	A	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(30.8%)	8.0%	23
Distance from 52-week high	(45.8%)	(31.4%)	31
EBIT to enterprise value	(1.8%)	(1.5%)	49
Free cash flow yield	1.0%	(1.0%)	60
Book value to price	0.05	0.28	19
Sales to price	0.22	0.31	41
Composite equity issuance, five years	12.3%	20.3%	42
Relative strength against the sector, log excess return	(0.58)	(0.14)	23

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$246.7M
Operating cash flow, four quarters	\$86.0M

Months of runway	not finite
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$57.6M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$527.2M	2025-12-31	2026-02-19	10-K	0001388658-26-000011
2	assets	us-gaap:Assets	\$1.0B	2025-12-31	2026-02-19	10-K	0001388658-26-000011
3	operating income	us-gaap:OperatingIncomeLoss	-\$99.9M	2021-12-31	2024-02-22	10-K	0001388658-24-000014
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsIncludableInNetEarnings	\$11.0M	2023-12-31	2024-02-22	10-K	0001388658-24-000014
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$367,000	2021-12-31	2024-02-22	10-K	0001388658-24-000014
6	total debt	us-gaap:LongTermDebt	\$9.7M	2021-12-31	2022-02-28	10-K	0001388658-22-000020
7	book equity	us-gaap:StockholdersEquity	\$279.5M	2021-12-31	2025-02-20	10-K	0001388658-25-000028
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$127.6M	2021-12-31	2023-02-23	10-K	0001388658-23-000007
9	total debt	us-gaap:LongTermDebt	\$21.3M	2020-12-31	2022-02-28	10-K	0001388658-22-000020
10	book equity	us-gaap:StockholdersEquity	\$341.6M	2020-12-31	2024-02-22	10-K	0001388658-24-000014
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$88.6M	2020-12-31	2022-02-28	10-K	0001388658-22-000020
12	net income	us-gaap:NetIncomeLoss	-\$44.6M	2025-12-31	2026-02-19	10-K	0001388658-26-000011
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$80.9M	2025-12-31	2026-02-19	10-K	0001388658-26-000011
14	assets	us-gaap:Assets	\$931.4M	2024-12-31	2026-02-19	10-K	0001388658-26-000011
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$747.1M	2025-12-31	2026-02-19	10-K	0001388658-26-000011
16	gross profit	us-gaap:GrossProfit	\$407.5M	2024-12-31	2026-02-19	10-K	0001388658-26-000011
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$591.8M	2024-12-31	2026-02-19	10-K	0001388658-26-000011
18	gross profit	us-gaap:GrossProfit	\$331.8M	2023-12-31	2026-02-19	10-K	0001388658-26-000011
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$492.7M	2023-12-31	2026-02-19	10-K	0001388658-26-000011
20	gross profit	us-gaap:GrossProfit	\$281.6M	2022-12-31	2025-02-20	10-K	0001388658-25-000028
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$410.9M	2022-12-31	2025-02-20	10-K	0001388658-25-000028
22	gross profit	us-gaap:GrossProfit	\$213.6M	2021-12-31	2024-02-22	10-K	0001388658-24-000014
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$322.8M	2021-12-31	2024-02-22	10-K	0001388658-24-000014
24	current assets	us-gaap:AssetsCurrent	\$702.8M	2025-12-31	2026-02-19	10-K	0001388658-26-000011
25	current liabilities	us-gaap:LiabilitiesCurrent	\$151.9M	2025-12-31	2026-02-19	10-K	0001388658-26-000011
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$803.4M	2025-12-31	2026-02-19	10-K	0001388658-26-000011
27	operating income	us-gaap:OperatingIncomeLoss	-\$57.4M	2025-12-31	2026-02-19	10-K	0001388658-26-000011
28	book equity	us-gaap:StockholdersEquity	\$152.7M	2025-12-31	2026-02-19	10-K	0001388658-26-000011
29	liabilities	us-gaap:Liabilities	\$867.3M	2025-12-31	2026-02-19	10-K	0001388658-26-000011
30	operating income	us-gaap:OperatingIncomeLoss	-\$125.2M	2023-12-31	2026-02-19	10-K	0001388658-26-000011
31	interest expense	us-gaap:InterestExpense	\$3.6M	2023-12-31	2024-02-22	10-K	0001388658-24-000014
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$46.3M	2025-12-31	2026-02-19	10-K	0001388658-26-000011
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.4M	2024-12-31	2026-02-19	10-K	0001388658-26-000011
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$33.9M	2024-12-31	2026-02-19	10-K	0001388658-26-000011
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$50.1M	2023-12-31	2026-02-19	10-K	0001388658-26-000011
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$40.4M	2023-12-31	2026-02-19	10-K	0001388658-26-000011
37	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$23.0M	2022-12-31	2025-02-20	10-K	0001388658-25-000028
38	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$29.8M	2022-12-31	2025-02-20	10-K	0001388658-25-000028
39	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$20.7M	2025-12-31	2026-02-19	10-K	0001388658-26-000011
40	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsIncludableInNetEarnings	\$11.0M	2023-12-31	2026-02-19	10-K	0001388658-26-000011
41	income tax	us-gaap:IncomeTaxExpenseBenefit	\$953,000	2025-12-31	2026-02-19	10-K	0001388658-26-000011
42	current assets	us-gaap:AssetsCurrent	\$645.8M	2024-12-31	2026-02-19	10-K	0001388658-26-000011
43	current liabilities	us-gaap:LiabilitiesCurrent	\$110.9M	2024-12-31	2026-02-19	10-K	0001388658-26-000011
44	assets	us-gaap:Assets	\$433.1M	2023-12-31	2025-02-20	10-K	0001388658-25-000028
45	assets	us-gaap:Assets	\$448.2M	2022-12-31	2024-02-22	10-K	0001388658-24-000014
46	shares outstanding	dei:EntityCommonStockSharesOutstanding	32,316,760	2026-02-12	2026-02-19	10-K	0001388658-26-000011
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	31,409,617	2025-02-13	2025-02-20	10-K	0001388658-25-000028